Autopsy report · NCT01377389

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

“Due to adverse events”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 10 months before it stopped.
• 30 participants enrolled.
• Results were posted on the registry 2 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

Ipilimumab; Leuprolide; Goserelin; Degarelix

Participants

30

Sites

1

Countries

United States

Trials that died the same way

• Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
  “Adverse Events” (88% match in meaning)
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
  “Other - Adverse Events” (86% match in meaning)
• Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery
  “Adverse Event” (85% match in meaning)
• Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)
  “investigation of adverse events in a related clinical study” (78% match in meaning)
• Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes
  “Unexpected non-serious adverse events” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.